Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alzamend Neuro's Enterprise Value is $4.70 Mil.
Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-12.39 Mil. Therefore, Alzamend Neuro's EV-to-EBIT ratio for today is -0.38.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alzamend Neuro's Enterprise Value is $4.70 Mil.
Alzamend Neuro's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-12.35 Mil. Therefore, Alzamend Neuro's EV-to-EBITDA ratio for today is -0.38.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Alzamend Neuro's Enterprise Value is $4.70 Mil.
Alzamend Neuro's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $0.00 Mil. Therefore, Alzamend Neuro's EV-to-Revenue ratio for today is .
Alzamend Neuro Enterprise Value Historical Data
The historical data trend for Alzamend Neuro's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alzamend Neuro's Enterprise Value
For the Biotechnology subindustry, Alzamend Neuro's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's Enterprise Value falls into.
Alzamend Neuro Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Alzamend Neuro's Enterprise Value for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (NAS:ALZN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Alzamend Neuro's current Enterprise Value is $4.70 Mil.
Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.39 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Alzamend Neuro's current Enterprise Value is $4.70 Mil.
Alzamend Neuro's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.35 Mil.
Alzamend Neuro's current Enterprise Value is $4.70 Mil.
Alzamend Neuro's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro Enterprise Value Related Terms
Thank you for viewing the detailed overview of Alzamend Neuro's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Alzamend Neuro (Alzamend Neuro) Business Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your 